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ARTICLE
Molecular basis for the disruption of Keap1–Nrf2
interaction via Hinge & Latch mechanism
Yuta Horie1,2,12, Takafumi Suzuki 1,12, Jin Inoue3,4,12, Tatsuro Iso1, Geoffrey Wells 5, Terry W. Moore6,
Tsunehiro Mizushima7, Albena T. Dinkova-Kostova8,9, Takuma Kasai 10,11, Takashi Kamei2,
Seizo Koshiba3,4✉ & Masayuki Yamamoto 1,3,4✉
The Keap1-Nrf2 system is central for mammalian cytoprotection against various stresses and
a drug target for disease prevention and treatment. One model for the molecular mechanisms
leading to Nrf2 activation is the Hinge-Latch model, where the DLGex-binding motif of Nrf2
dissociates from Keap1 as a latch, while the ETGE motif remains attached to Keap1 as a hinge.
To overcome the technical difficulties in examining the binding status of the two motifs
during protein-protein interaction (PPI) simultaneously, we utilized NMR spectro-
scopy titration experiments. Our results revealed that latch dissociation is triggered by low-
molecular-weight Keap1-Nrf2 PPI inhibitors and occurs during p62-mediated Nrf2 activation,
but not by electrophilic Nrf2 inducers. This study demonstrates that Keap1 utilizes a unique
Hinge-Latch mechanism for Nrf2 activation upon challenge by non-electrophilic PPI-inhibiting
stimuli, and provides critical insight for the pharmacological development of next-generation
Nrf2 activators targeting the Keap1-Nrf2 PPI.
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The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) plays a central role in cytoprotectionagainst electrophilic and oxidative stress1. Under basal
conditions, the Nrf2 protein is maintained at relatively low con-
centrations, as Nrf2 is constitutively ubiquitinated by Keap1
(Kelch-like ECH-associated-protein 1), an adaptor component of
the Cul3 (Cullin 3)-based ubiquitin E3 ligase complex, and tar-
geted for proteasomal degradation2,3. Upon exposure to electro-
philes or oxidants, Nrf2 ubiquitination ceases, leading to its
stabilization and nuclear translocation/accumulation, followed by
inducible expression of Nrf2 target genes4–6.
The Neh2 domain of Nrf2 is located at the N-terminus of the
transcription factor and harbors two Keap1-binding motifs, a
low-affinity DLGex motif and a high-affinity ETGE motif7,8.
Whereas the DLGex motif possesses a three-helix structure and
binds weakly to Keap1-DC (Double glycine repeat or Kelch, plus
C-terminal) domain, the ETGE motif is a single β-hairpin
structure that binds tightly to a pocket in Keap1-DC domain in a
key-and-lock manner8,9. The binding of these two motifs of Nrf2
to the Keap1 homodimer (i.e., two-site binding) is strictly
required for ubiquitination and proteasomal degradation of
Nrf27,10. Analytical centrifugation analyses support this notion,
showing that the stoichiometry of the Keap1–Nrf2 complex is
2:111. The two-site binding mode is supported by the finding that
somatic mutations in various cancer cells occur with very high-
frequency in the DLGex and ETGE motifs of Nrf212,13. These
mutations disrupt the two-site binding of Keap1–Nrf2 and lead to
constitutive accumulation of Nrf2, supporting malignant growth
of cancer cells14.
Considering the difference in binding affinity between the
DLGex and ETGE motifs and the necessity for the two-site
binding for the Keap1-mediated ubiquitination of Nrf2, we
hypothesized that the two-site binding is the key regulatory nexus
of the Keap1–Nrf2 system. Based on a number of critical obser-
vations related to the two-site binding model of the Keap1–Nrf2
interaction, we have proposed the Hinge-Latch model15,16. For
instance, immunoprecipitation or pull-down experiments have
not detected dissociation between Keap1 and Nrf2 after exposure
to Nrf2-activating compounds3,17–21. In the Hinge-Latch model,
the Keap1–DLGex interaction first dissociates as a latch, while the
Keap1-ETGE remains bound as a hinge regardless of the presence
of Nrf2-activating stimuli7,8,15–17.
A multitude of Nrf2-activating compounds have been reported,
most of which are electrophilic and readily react with cysteine–
thiols in Keap119,21. Several cysteine sensors for electrophilic Nrf2
activators have been identified in Keap122–25. Modifications of
reactive cysteine residues in Keap1 have been demonstrated using
mass spectrometry analyses19,21,26–30. Cys151 in the BTB (Broad-
complex, Tramtrack and Bric-a-Brac) domain of Keap1 is the
sensor for many Nrf2 activators, including 1-[2-cyano-3,12-diox-
ooleana-1,9(11)-dien-28-oyl] imidazole (CDDO-Im) and sulfor-
aphane (SFN)23,24. Another functional sensor is Cys288; it is
located in the IVR (Intervening Region) of Keap1, and is modified
by 15d-PGJ2 (15-deoxy-Δ12,14-prostaglandin J2)24. Although
modification of Cys151 is considered to disrupt Keap1–Cul3
interaction11, modification of Cys288 is speculated to induce a
conformational distortion to the Keap1-DC domain owing to the
proximity between IVR and DC domains, subsequently leading to
dissociation of Keap1–DLGex interaction (i.e., utilizing the Hinge-
Latch mechanism).
In addition to electrophilic Nrf2-activating compounds, dis-
ruptors of the Keap1–Nrf2 protein-protein interactions (PPI)
have been attracting increasing attention. For instance, p62/
Sequestosome-1 (hereafter, referred to as p62) accumulates in
autophagy-deficient hepatocytes and inhibits the Keap1–Nrf2
interactions31. The KIR (Keap1 Interaction Region) of p6232
harbors an STGE motif, which acquires a high affinity for the
Keap1-DC domain through phosphorylation of the serine
residue33. In addition to p62, pharmacological non-electrophilic
Keap1–Nrf2 PPI inhibitors have been developed. For instance,
aryl bicyclic sulfonamide-based Keap1–Nrf2 PPI inhibitors such
as PRL29534 and NG26235 have been shown to stabilize Nrf2
protein in cells. However, it is unknown how these Keap1–Nrf2
PPI inhibitors affect Keap1–DLGex binding and Keap1-ETGE
binding.
In experiments using titration nuclear magnetic resonance
(NMR) spectroscopy, the NMR signals corresponding to the
intrinsically disordered Neh2 domain (comprising 98 amino
acids) of Nrf2 experience line-broadening upon binding to the
large molecular weight protein Keap1. Conversely, upon release
from Keap1, NMR signals corresponding to the Neh2 domain
recover by narrowing of the linewidth. Using this approach, we
previously demonstrated the interaction between the Keap1-DC
domain with the Nrf2-Neh2 domain and their molecular
characteristics7. However, as we had utilized the DC domain
protein that lacked the dimer-forming BTB domain of Keap1, and
our amino-acid signal assignments were relatively limited,
therefore we could not test the Hinge-Latch mechanism at
that time.
To test the Hinge-Latch model, it is essential to examine the
status of Keap1–DLGex binding and Keap1-ETGE binding
simultaneously. However, concomitant measures of this two-site
binding using conventional methodologies are technically diffi-
cult. Therefore, in this study, we developed a titration NMR
approach. We also established a system in which full-length
Keap1 homodimer interacts with isotope-labeled Neh2 protein
and designed a fine detection system for signal recovery from
individual interacting sites. We found that pharmacological
Keap1–Nrf2 PPI inhibitors, NG262 and PRL295, disrupt the
Keap1–DLGex binding preferentially to that of the Keap1-ETGE
binding. Similarly, a phosphorylated p62 peptide also disrupts the
Keap1–DLGex binding. In contrast, the electrophilic Nrf2-
activating compounds CDDO-Im, SFN, and 15d-PGJ2 do not
disrupt the Keap1–DLGex or the Keap1-ETGE interactions. Our
results unequivocally demonstrate that Keap1–Nrf2 PPI inhibi-
tors and p62, but not electrophilic cysteine-targeting compounds,
utilize the Hinge-Latch mechanism for Nrf2 activation.
Results
NMR titration approach for two-site PPI assessment. To
ascertain whether the Hinge-Latch mechanism operates, it is
essential to be able to verify the status of Keap1–DLGex binding
and Keap1-ETGE binding independently. However, our previous
attempts were hampered by the technical difficulty of validating
the two-site binding event within one protein complex that
comprises three subunits, i.e., two Keap1 proteins (in the context
of the Keap1 homodimer) binding individually to two sites in one
Nrf2 protein (Fig. 1a, left). In this study, we reasoned that titra-
tion NMR spectroscopy could provide a powerful means for
observing the binding of the two sites independently and over-
come this problem.
As shown in Fig. 1b, the Neh2 domain (98 amino acids) of
Nrf2 is intrinsically disordered and, upon binding to the large
molecular weight protein Keap1 dimer (molecular weight 140
kDa), NMR signals corresponding to the Neh2 domain
experience line-broadening. The line-broadening likely accounts
for their interaction rather than a conformational exchange,
because co-crystal structures of Keap1–DLGex and Keap1-ETGE
have shown that the same pocket of Keap1 binds to DLGex and
ETGE8,9. On the other hand, when released from the Keap1
homodimer, NMR signals corresponding to the binding sites of
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the Neh2 domain recover, shown by narrowing of the linewidth
(Fig. 1a, right). In fact, we previously demonstrated that the
Keap1-DC domain (molecular weight ~30 kDa for the monomer)
interacts with the Neh2 region of Nrf2 by NMR titration
experiments7.
In this study, therefore, we have addressed this issue by
utilizing titration NMR spectroscopy, as the unique mode of
interaction between Keap1 and Nrf2 allows us to apply this
technique for the two-site PPI analysis. For this purpose, we first
labeled the Neh2 domain of Nrf2 with 13C and 15N during its
expression and generated the Keap1 dimer–Neh2 complex
(Fig. 1b, left). As this complex did not give rise to any clear-cut
signal, we then titrated the complex with various components to
observe the appearance of a signal. Based on the Hinge-Latch
model, we surmised the presence of the ETGE single-binding
condition (Fig. 1b, middle) and the DLGex and ETGE double-
dissociated condition (right). We expected to detect binding of
each individual site and to validate these three conditions by
NMR titration (Fig. 1c).
Full-length Keap1 and labeled Neh2 domain structure. To
conduct NMR structure analyses, in the previous study, we used a
truncated Keap1-DC protein, which lacks the N-terminal region
containing the BTB domain7. The N-terminal region is required
for the Keap1–Keap1 protein interaction and the formation of
Keap1 homodimer36. As the lack of N-terminus may affect
binding of Keap1 to the DLGex and ETGE motifs of Nrf2, we
decided to use full-length Keap1 to validate the Neh2 domain
structure and the two-site-binding Hinge-Latch model. To this
end, we first expressed full-length mouse wild-type Keap1-6×His
in bacteria by the transformation of an expression plasmid vector,
and performed purification by Ni2+ affinity column chromato-
graphy, anion exchange chromatography, and gel filtration
chromatography (Fig. 1d). This approach resulted in the pre-
paration of highly purified recombinant full-length Keap1 protein
(Fig. 1e).
To prepare the Neh2 protein for the NMR experiment, 6xHis-
GST tagged Neh2 protein was expressed in bacteria transformed
with plasmid vector. The 6xHis-GST tagged Neh2 protein was
uniformly labeled by culturing in M9 minimal medium in which
carbon and nitrogen were replaced with stable isotopes 13C
and 15N (Fig. 1f). After Ni2+ affinity column chromatography,
the 6xHis-GST tag was cleaved by turbo TEV protease and
removed by a second Ni2+ affinity chromatography step (Fig. 1g).
Thus, we also prepared highly purified stable isotope-labeled
recombinant Neh2 domain protein.
Assignment of the sequence-specific backbone of Neh2.
Utilizing purified labeled Neh2 protein, we measured the 2D
transverse relaxation optimized spectroscopy (TROSY)-HSQC
NMR spectrum to detect the HN peaks from the main chain of
amino acids of the labeled Neh2 domain protein. As previously
reported7, the TROSY-HSQC spectrum of unbound Neh2
exhibited a limited chemical shift dispersion (Fig. 2a). Backbone
amide protons resonate between 7.7 and 8.7 ppm around the
random coil region of 8.0–8.5 ppm37, a feature typical of intrin-
sically disordered proteins38. Except for overlapped resonances,
we were able to make the sequence-specific backbone assignments
for Neh2. Assigned amino acids are indicated in bold in Fig. 2b.
Fig. 1 Verification of the Hinge-Latch model by NMR titration method.
a Working hypothesis for the Hinge-Latch model of activation of Nrf2 by
electrophilic and non-electrophilic inducers. This model was proposed based
on the two-site binding model; DLGex and ETGE motifs of Nrf2 bind
individually to the similar pocket structure in the Keap1-DC domain of the
Keap1 homodimer. According to the Hinge-Latch model, DLGex site
dissociation alone sufficiently disturbs the ubiquitin ligase activity of the
Keap1 complex14. b Hypothetical statuses of the Keap1–Nrf2 complex. As
ETGE motif has a 200-fold higher binding affinity to Keap1-DC domain than
DLGex motif does, three statuses of the Keap1–Nrf2 protein complex can be
postulated; two sites bound (left), only ETGE site bound (middle), and fully
dissociated (right). c Rationale of the NMR titration technique. A schematic
depiction of a 1D NMR peak is shown. The Neh2 domain of Nrf2 (98 amino
acids) is intrinsically disordered and, upon binding to the large molecular
weight protein Keap1 dimer (molecular weight ~140 kDa), the NMR signals
corresponding to the Neh2 domain experience line-broadening. On the other
hand, when released from Keap1 homodimer, the NMR signals corresponding
to the binding sites of Neh2 domain recover by narrowing of linewidth. The
NMR titration experiment enables us to detect the binding of each individual
site and to validate the three conditions shown in b. d Scheme for induction
and expression of recombinant full-length Keap1-6xHis protein. e Purification
processes of recombinant full-length Keap1-6xHis protein. f Scheme for
induction and expression of recombinant 6xHis-GST-13C15N Neh2 protein.
g Purification processes of recombinant 6xHis-GST-13C15N Neh2 protein.
The protein was purified by Ni2+ affinity column chromatography and gel
filtration chromatography. For the preparation of Neh2 domain, after Ni2+
affinity column chromatography, 6xHis-GST tag was cleaved by turbo TEV
protease and removed by second Ni2+ affinity chromatography (*). M
molecular marker, L lysate, FT flow through, I input, E eluate.
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Unlike the ETGE motif that forms a β-hairpin structure and
binds tightly to the Keap1-DC domain9, the DLGex motif forms
three helical regions (Helix-1, 19–25; Helix-2, 28–30; Helix-3,
34–37) in the Keap1-bound form (Fig. 2c) (PDB 3WN7)8. We
assigned amino acids corresponding to Helix-1 (ILe20, Asp21,
Ile22, Leu23, Trp24, and Arg25) and Helix-2 (Ile28, Asp29, and
Leu30) in the DLGex motif, whereas amino acids corresponding
to Helix-3 could not be assigned. Amino acids corresponding to
ETGE motif (Gln75, Leu76, Asp77, Glu78, Glu79, Thr80, Gly81,
Glu82, Phe83, and Leu84) were also assigned (Fig. 2d). Keap1
dimer is unstable at pH <8.0 at protein concentrations suitable for
the sequence-specific backbone assignment. Despite efforts for
years, we still could not accomplish the full backbone assignment.
Nonetheless, in this study, we have succeeded substantial
extension of the assignment from our previous assessment of
the Neh2 domain NMR structure7 and this enabled us to execute
informative NMR titration experiments.
Full-length Keap1 binds to Neh2 via DLGex and ETGE motifs
in a 2:1 stoichiometry. We performed NMR titration analyses to
map the two binding sites in the Neh2 domain of Nrf2 with the
full-length Keap1 homodimer. In accordance with our expecta-
tion, we found that there was an increasing disappearance of the
resonance signals corresponding to the DLGex and ETGE motifs
in the 2D TROSY-HSQC spectra upon complex formation with
full-length Keap1 (Fig. 3a–c). The loss of NMR signals is most
likely owing to an increase in the apparent molecular weight
caused by the protein complex formation. We titrated 50-μM
labeled Neh2 domain protein with either an equivalent amount or
double the amount of Keap1 protein (Fig. 3b, c, respectively).
In the bar graph representations of signal peak intensity, we
calculated the signal peak intensity under each condition by
setting the signal peak observed with the unbound Neh2 domain
protein to 100% (Fig. 3d–f). Although the relative intensity of
Helix-1 in DLGex motif was reduced to ~40% by the addition of
an equal amount of Keap1 protein, the relative intensity of Helix-
2 in the DLGex motif was reduced to ~70% (Fig. 3e), suggesting
that Helix-1 interacts with Keap1 preferentially and more tightly
compared with Helix-2. The relative intensity of the ETGE motif
was reduced to ~20–30%, indicating that ETGE motif interacts
with Keap1 much more tightly than the DLGex motif. These
results are consistent with previous reports that the ETGE motif
of Nrf2 has a higher binding affinity to Keap1 than the DLGex
motif when Keap1-DC domain lacking the BTB domain-
mediated homodimerization was used7.
The signals corresponding to both helices disappeared almost
completely on the addition of twofold excess amount of Keap1
protein (Fig. 3f). Of note, the signals from the ETGE motif also
disappeared completely in this condition, indicating the forma-
tion of two-site-binding between the Keap1 homodimer and both
DLGex and ETGE motifs in Neh2. These results strongly support
the Hinge-Latch model in which Keap1 homodimer binds to the
Neh2 domain of Nrf2 with 2:1 stoichiometry via the lower-
affinity DLGex motif and the higher affinity ETGE motif.
Closer inspection of the signal peak intensity revealed that
there were still signals from the N-terminus (Leu4, Glu5, and
Leu6) and C-terminus (Gly98) of Nrf2 (Fig. 3d–f), indicating that
the N- and C-terminal regions of the Neh2 domain of Nrf2 do
not interact with Keap1 under these assay conditions, resulting in
slow relaxation. By contrast, the signals corresponding to the
intervening region between DLGex and ETGE motifs (Leu54,
Glu57, Ala69, Phe70, and Gln73) had disappeared, implying that
this region also associates with Keap1 following the interaction
via DLGex and ETGE motifs.
Keap1–Nrf2 PPI inhibitors inhibit the Keap1–DLGex interac-
tion preferentially. The Keap1–Nrf2 PPI inhibitors are very
attractive next-generation Nrf2 activators, because PPI inhibitors
are more specific and less toxic than thiol-modifying chemicals39.
The Keap1–Nrf2 PPI inhibitors are designed to bind the Keap1-
DC pocket, and thereby interfere with Nrf2 binding. However,
the precise molecular details of how PPI inhibitors affect the
interactions between Nrf2 and Keap1 remain elusive. To address
this issue, we examined the effects of low-molecular-weight
Keap1–Nrf2 PPI inhibitors, PRL29534 and NG26235, both of
which bind to the Keap1-DC domain and activate Nrf2.
PRL295 binds to the pocket located in the Keap1-DC β-
propeller structure (PDB 6UF0). NG262 also binds to the same
pocket. This structural examination suggests that both PRL295
and NG262 compete with the binding motifs in the Neh2
domain. Therefore, we hypothesized that the molecular mechan-
ism of action of these compounds can be explained by the Hinge-
Latch mechanism. Specifically, we postulated a scenario in which
the DLGex–Keap1 interaction is dissociated first by these
compounds, whereas the Hinge site may also dissociate if the
compounds are in vast excess.
To test this hypothesis, we conducted a new series of NMR
titration experiments. We titrated the Keap1–Neh2 interaction
(full interaction; Keap1:Neh2 ratio= 2:1) by using PRL295 or
NG262. We first mixed 50-μM-labeled Neh2 domain (Supple-
mentary Fig. 1a) with 100-μM Keap1 protein and generated the
Keap1–Neh2 fully interacting complex (Supplementary Fig. 1b).
We then titrated this protein complex with increasing amounts of
PRL295 or NG262. We found that PRL295 nicely inhibited the
Keap1–Neh2 interaction even at an equimolar concentration
Fig. 2 Assignment of HN peaks of amino-acid main chain of labeled Neh2.
a 2D TROSY-HSQC spectrum shows HN peaks of the main chain of amino
acids of labeled Neh2 domain protein. b Alignment of mouse Neh2 domain.
The assigned amino acids are in bold. The amino acids in Helix-1, Helix-2,
and Helix-3 in the DLGex motif are underlined. c, d Structure of DLGex (c)
and ETGE (d) motifs associating with the Keap1 pocket. Note that the
DLGex motif possesses three-helix regions (Helix-1, 19–25; Helix-2, 28–30;
Helix-3, 34–37) (PDB 3WN7, ref. 8), whereas the ETGE motif forms a
β-hairpin structure (PDB 2DYH, ref. 16). We have proposed the two-site
binding model in which each motif binds to a similar pocket structure in the
Keap1-DC domain of the Keap1 homodimer (as shown in Fig. 1a).
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(Supplementary Fig. 1c) and fivefold excess of the compound
fully inhibited the interaction (Supplementary Fig. 1d). NG262
also showed a similar titration profile, thus, the Keap1–Neh2
interaction dissociated with equimolar concentration of NG262
(Supplementary Fig. 1e) and fivefold excess fully inhibited the
interaction (Supplementary Fig. 1f). These results thus demon-
strate that the PPI inhibitors PRL295 and NG262 dissociate the
Keap1–Neh2 interaction.
Detailed inspection of these titration experiments revealed
marked difference between the DLGex–Keap1 and ETGE–Keap1
bindings. It should be noted that the NMR signals corresponding
to the DLGex motifs reached almost half of the full signals by the
addition of equal amounts of PRL295 (Fig. 4a) or NG262
(Fig. 4b). The DLGex motif signal increased to an almost full
(non-complexed) signal level by the addition of twofold excess
PRL295 or NG262. In this case, the ETGE–Keap1-binding signals
increased to approximately half of the full signals. These results
unequivocally demonstrate that both compounds inhibit
the DLGex–Keap1 binding preferentially compared with
ETGE–Keap1 binding, strongly supporting the contention that
these PPI inhibitors act through the Hinge-Latch mechanism.
This conclusion is further supported by the merge images of
PRL295-DLGex and NG262-DLGex (Supplementary Fig. 2a and
b, respectively). The binding profiles of these compounds are very
similar and deeply localized in the pocket in the Keap1-DC
structure. Closer inspection of the titration profiles further
revealed that Helix-2 in the three helices of DLGex dissociated
more quickly from the Keap1 pocket than Helix-1 did in the
titration experiments by PRL295 and NG262 (Fig. 4a, b,
respectively). Helix-3 could not be examined in this study. The
Fig. 3 Keap1 binds to Neh2 domain of Nrf2 via DLGex and ETGE motifs at 2:1 stoichiometry. a–c 2D TROSY-HSQC spectrum shows HN peaks of the
main chain of amino acids of labeled Neh2 domain protein in the absence of Keap1 (a), in the presence of equal amount of Keap1 (b) or twofold excess of
Keap1 (c). d–f Relative peak intensity of the NMR signal of Neh2 only (d), Neh2:Keap1= 1:1 (e) or Neh2:Keap1= 1:2 (f). Relative peak intensity of the NMR
signal of each amino-acid residue is calculated after the addition of Keap1, setting the peak intensity of Neh2 only as 100%. Note that we quantitated it by
the concentration of the individual Keap1 protomers rather than homodimer here.
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relative intensities corresponding to DLGex increase to a greater
extent in response to these inhibitors. Inspection of the merge
images of PRL295-DLGex and NG262-DLGex further revealed
that the binding positions of both PPI inhibitors in the Keap1
pocket heavily overlapped with that of Helix-2 (Fig. 4c, d). These
results indicate that PRL295 and NG262 preferentially inhibit the
DLGex–Keap1 interaction via competing with Helix-2 of DLGex
for binding to Keap1. These findings provide valuable informa-
tion for the development of next-generation Nrf2 inducers that
specifically inhibit the Keap1–Nrf2 interaction without electro-
philic insults.
Electrophilic Nrf2 inducers do not inhibit the Keap1–Neh2
interaction. Electrophilic Nrf2 activators belong to several classes
based on the utilization of specific sensor cysteine residues in
Keap124,25,40. The best characterized class of Nrf2 activators are
Cys151-targeting compounds including CDDO-Im and SFN23,24.
Therefore, we next tested the effect of CDDO-Im and SFN on the
Keap1–Neh2 interaction.
We first mixed 50-μM labeled Neh2 domain protein
(Supplementary Fig. 3a) with 100-μM Keap1 protein and
generated the Keap1–Neh2 protein complex in which most of
the NMR signals were disappeared (Supplementary Fig. 3b). We
then titrated the protein complex with CDDO-Im (Fig. 5a). In
contrast to the PPI inhibitors, addition of CDDO-Im at even the
maximally soluble concentration (10-fold excess) did not increase
the NMR signals corresponding to the DLGex or ETGE motifs
(Supplementary Fig. 3c, d; Fig. 5a), indicating that CDDO-Im
does not dissociate the Keap1–Neh2 interaction.
Similarly, addition of SFN at even the maximally soluble
concentration (10-fold excess) did not increase the signals
corresponding to the DLGex or ETGE motifs (Supplementary
Fig. 3e, f; Fig. 5b), indicating that the SFN treatment did not
dissociate the DLGex and ETGE motifs from Keap1. These results
Fig. 4 Keap1–Nrf2 PPI inhibitors preferentially inhibit the Keap1–DLGex interaction. a, b NMR titration experiment of labeled Neh2–Keap1 complex (1:2)
by the addition of equal amount or twofold excess of PPI inhibitor, PRL295 (a) and NG262 (b). The relative peak intensity of the NMR signal of each
residue was calculated (set at 100% for Neh2 only). c, d Merged images of DLGex with PRL295 (c) or NG262 (d) associating with Keap1 pocket. Image of
co-crystal Keap1-PRL295 complex (PDB 6UF0, ref. 34) was used. Note that bindings of these compounds heavily overlap with that of DLGex Helix-2 (c, d)
and these compounds titrate the binding of Helix-2 more efficiently than that of Helix-1 (a, b).
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demonstrate that CDDO-Im and SFN activate Nrf2 without
disrupting the Keap1–Neh2 interaction, consistent with the
notion that modification of Cys151 is considered not to disrupt
the Keap1–Neh2 interaction but to disrupt the Keap1–Cul3
interaction instead11. Curiously, we also found that SFN increased
the signals corresponding to Leu76, but the significance or the
molecular basis for these signals remains to be clarified.
15d-PGJ2 belongs to another class of electrophilic Nrf2
activators, those that modify Cys288 of the IVR domain in
Keap1. As a modification of Cys288 is speculated to be conveyed
as conformational distortion to the Keap1-DC domain owing to
the proximity between the IVR and DC domains, we surmised
that the modification of Cys288 by 15d-PGJ2 might dissociate the
Keap1–DLGex binding (i.e., utilize the Hinge-Latch mechanism).
To test this hypothesis, we examined whether 15d-PGJ2 disrupt
Keap1–DLGex binding (Fig. 5c; Supplementary Fig. 3g, h).
Unexpectedly, we found that 15d-PGJ2 did not increase the
signals of DLGex and ETGE motifs, indicating that 15d-PGJ2
activates Nrf2 without affecting the Keap1–Neh2 interaction.
Taken together, these results unequivocally demonstrate that
representative classical electrophilic Nrf2 inducers, CDDO-Im,
SFN, and 15d-PGJ2, which are known to modify cysteine sensors
in Keap1, and consequently activate Nrf2, do not act through the
Hinge-Latch mechanism.
p62-KIR peptides preferentially inhibit the Keap1–DLGex
interaction. Next, we explored whether other Nrf2-inducing
machineries that are known to affect the binding between Nrf2
and Keap1 in a physiological context employ the Hinge-Latch
mechanism. To the best of our knowledge, the most characterized
inducer in vivo that competitively binds to Keap1 is p62/
Sequestosome-1, an adaptor/chaperone of cellular proteins gui-
ded to autophagy31. Our previous studies have shown that the
KIR (Keap1-Interacting Region) of p62 contains an STGE
sequence32 and the phosphorylated STGE (pSTGE) sequence has
a higher affinity for the Keap1-DC than non-phosphorylated
STGE does33. Therefore, in order to test how p62 affects the
Keap1–Neh2 interaction, we tested non-phosphorylated and
phosphorylated KIR peptides using the titration NMR technique.
To this end, 50-μM labeled Neh2 domain protein was bound to
100-μM Keap1 protein at a molar ratio of 1:2 (Supplementary
Fig. 5 Electrophilic Nrf2 activators do not disrupt the Keap1–Neh2 interaction. NMR titration experiment of labeled Neh2–Keap1 complex (1:2) with
electrophilic Nrf2 inducers, CDDO-Im a, SFN b, and 15d-PGJ2 c. Note that none of these compounds titrate the Neh2–Keap1 binding efficiently in the
exploited range of concentrations. The relative peak intensity of the NMR signal of each amino-acid residue is calculated after setting Neh2 only as 100%.
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Fig. 4a), and then titration experiments were performed using the
phosphorylated p62-KIR peptide (P-p62-KIR); the Keap1–Neh2
complex was titrated using a 5-, 10-, 20-, 30-, or 100-fold excess
of P-p62-KIR peptide (Fig. 6a, b; Supplementary Fig. 4b, c). We
found that the P-p62-KIR peptides preferentially increased the
signals corresponding to the DLGex motif compared to the ETGE
motif in a concentration-dependent manner. Thus, the signals for
DLGex appeared even with a fivefold excess of P-p62-KIR
(Fig. 6a; light green bars), whereas the signals for ETGE only
started appearing when 20-fold excess was used (Fig. 6b; blue
bars), and was saturated with a 100-fold excess (black bars) of P-
p62-KIR. These data show that a 100-fold excess of P-p62-KIR
peptide can compete with the ETGE motif for binding to Keap1.
Of note, we found that Helix-2 in DLGex motif dissociated more
quickly from the Keap1 pocket than Helix-1 did during the
titration by P-p62-KIR (Fig. 6c), which is consistent with the
observation using the Keap1–Nrf2 PPI inhibitors. These results
thus demonstrate that the P-p62-KIR peptide disrupted the
binding of DLGex–Keap1 (Latch site; Fig. 6c) more efficiently
than that of ETGE–Keap1 (Hinge site; Supplementary Fig. 4d)
and the dissociation of the DLGex motif starts from Helix-2
(Fig. 6d).
We also examined whether non-phosphorylated p62-KIR
(Non-P-p62-KIR) peptide affects the Keap1–Neh2 interaction.
We tested 20- and 100-fold excess concentrations of the Non-P-
KIR peptide, and found that this peptide, albeit weakly, gave rise
to increase of the signals corresponding to the DLGex motif
(Supplementary Fig. 5a, b). This Non-P-p62-KIR peptide could
only suppress partially the ETGE–Keap1 binding (Supplementary
Fig. 6c). Overall, the efficiency of DLGex dissociation by Non-P-
p62-KIR is much lower than that by the P-p62-KIR peptide, in
full agreement with the report that phosphorylation of p62-KIR
increases markedly its binding affinity for Keap133.
These results strongly support the notion that the Hinge-Latch
mechanism is functional in vivo. The pSTGE motif in the P-p62-
KIR peptide interferes with binding of DLGex of Neh2 to Keap1
thus opening the Latch site, which suppresses efficient ubiquiti-
nation and rapid degradation of Nrf2. Taken together, this study
supports the contention that the Hinge-Latch mechanism is
operating in the Nrf2 activation caused by p62 accumulation
induced by autophagy impairment as well as by pharmacological
non-electrophilic Keap1–Nrf2 PPI inhibitors, but not classical
electrophilic Nrf2 inducers.
Discussion
This study addresses the long-lasting question of how electro-
philes and non-electrophilic PPI inhibitors target Keap1 to acti-
vate Nrf2. The cysteine–thiol-based sensor activity of Keap1 has
been examined extensively20–25,40. Similarly, various structure–
function analyses of the Keap1–Nrf2 interaction have revealed the
importance of the two-site binding between the Keap1 homo-
dimer (i.e., two DC domains) and the Neh2 domain of Nrf2 (via
DLGex and ETGE motifs)7,8,10,15,16, and we proposed the Hinge-
Latch model as a plausible mechanism for the Keap1-mediated
Nrf2 activation15,16. This model is based on the fact that the
DLGex and ETGE motifs show approximately two orders of
magnitude difference in the binding affinity to the Keap1-DC
domain7. Various lines of evidence including somatic mutation
analyses in clinical cancer studies support the presence of this
model12,13. However, the model has not been validated to date
owing to technical difficulties in examining the DLGex–Keap1
binding and ETGE–Keap1 binding simultaneously. To overcome
this problem, in this study we utilized NMR titration, which is
capable of simultaneous and sequence-specific assignment of the
DLGex and ETGE motifs. Utilizing this method, we found that
the Hinge-Latch mechanism operates during the activation of
Nrf2 by p62 accumulation (which can be induced by autophagy
deficiency) as well as pharmacological Keap1–Nrf2 PPI inhibitors
such as NG262 and PRL295, but not by electrophilic Nrf2
inducers such as CDDO-Im, SFN, or 15d-PGJ2 (Fig. 7).
Moreover, our current study unequivocally demonstrates that
pharmacological Keap1–Nrf2 PPI inhibitors, NG262 and PRL295,
preferentially disrupt the DLGex–Keap1 binding compared with
the ETGE–Keap1 binding, confirming the Hinge-Latch model.
This fact strongly argues that these PPI disruptors preferentially
interfere with the DLGex–Keap1 binding owing to the lower
affinity of the DLGex motif for Keap1 when compared with the
ETGE motif7. The DLGex motif possesses three-helix regions
(Helix-1, 19–25; Helix-2, 28–30; Helix-3, 34–37)8 and our current
assignment of signals allowed us to detect the binding of Helix-1
and Helix-2. Notably, the Helix-2 regions (28–30) were much
more profoundly affected by the PPI disruptors than the Helix-1
Fig. 6 Phosphorylated p62-KIR peptide preferentially inhibits
Keap1–DLGex interaction. a Relative peak intensity of each amino-acid
residue of Neh2 in the Neh2–Keap1 complex in the titration experiments by
the addition of five- and tenfold excess of phosphorylated p62-KIR (P-p62-
KIR) peptide. Relative peak intensity of the NMR signal of each residue is
calculated setting Neh2 only as 100%. b Relative peak intensity of each
amino-acid residue of Neh2 in the Neh2–Keap1 complex by the addition of
20- and 100-fold of P-p62-KIR peptide. c Relative peak intensity of the
amino-acid residues within the DLGex motif after the addition of P-p62-KIR
peptide. Closed and open circles indicate the amino-acid residues
corresponding to Helix-1 and Helix-2, respectively. d Merged structural
images of the Keap1-DC with the DLGex and P-p62-KIR. Note that binding
of P-p62-KIR heavily overlaps with that of DLGex Helix-2 d and the P-p62-
KIR titrates the binding of Helix-2 more efficiently than that of Helix-1 (a, b).
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region (19–25). This observation demonstrates that Helix-2 is
much more sensitive to the PPI disruptors than Helix-1. This
notion is supported by the protein structure assignments in which
the binding of the PPI inhibitors nicely overlaps with the binding
interface of Helix-2. We surmise that this information will be
crucial for the design of novel Keap1–Nrf2 PPI inhibitors capable
of efficient disruption of the DLGex–Keap1 interaction in
the future development of next-generation Nrf2 inducers.
It has been shown that Keap1 is degraded through the autop-
hagy pathway41. Specific protein degradation process through the
autophagosome is referred to as selective autophagy32. Selective
autophagy has an important role in physiological as well as
pathological processes, including neurodegenerative diseases and
oncogenesis42. The decline of autophagy is always accompanied by
the accumulation of p6243. In this regard, many lines of experi-
mental evidence have revealed that a high-level accumulation of
p62 promotes the activation of Nrf232, but the molecular
mechanism underlying the p62-mediated Nrf2 activation remained
to be clarified. By use of NMR titration, this study demonstrates
that the Hinge-Latch mechanism is the mechanism operating
during Nrf2 activation by the p62 accumulation. Thus, the Hinge-
Latch mechanism operates for cellular biological processes as well
as PPI inhibitors.
Of note, although equimolar amounts of NG262 or PRL295
effectively disrupted the Keap1–Neh2 interaction, more than a
20-fold excess of the p62-KIR peptide was required for disruption
of the Keap1–Neh2 interaction. We envisage that this difference
reflects the presence of complex molecular interactions within the
intracellular operation of the Hinge-Latch mechanism. One
plausible explanation for the difference is to consider the p62
protein oligomerization via PD1 and UBA domains44,45, which
are absent in the p62-KIR peptide. The oligomerization of p62 is
expected to enhance the local concentration of p62 protein and
thus may effectively disrupt the DLGex–Keap1 interaction in
cells. Supporting this possibility, p62 is known to be an Nrf2
target gene5, implying that positive feedback regulation by Nrf2
increases p62 levels in cells and helps to disrupt the
DLGex–Keap1 interaction. An alternative explanation is that
additional protein(s) assist the interaction of p62 and Keap1-DC
domain in vivo46,47, which are absent in our in vitro titration
experiment.
Another important finding in this study is that the electrophilic
Nrf2 activators, including CDDO-Im, SFN, and 15d-PGJ2 do not
affect the Keap1–Nrf2 interaction. As the sensor Cys151 for
CDDO-Im and SFN is located in the BTB domain of Keap1,
distant from the Latch site, it has been assumed that these two
compounds utilize mechanisms other than the Hinge-Latch
model. Consistent with this assumption, a Förster resonance
energy transfer study in live cells expressing fluorescently-tagged
Keap1 and Nrf2 and has shown that electrophilic inducers do not
disrupt the Keap1–Nrf2 interaction48. In this regard, there
remained a possibility that 15d-PGJ2 may use the Hinge-Latch
mechanism, because the sensor Cys288 for 15d-PGJ2 is located in
the IVR domain of Keap1, in a relatively close position to the
Latch site. However, our current study clearly shows that similar
to CDDO-Im and SFN, 15d-PGJ2 does not use the Hinge-Latch
mechanism.
As for the electrophilic inactivation of the Keap1 ubiquitin
ligase activity, we propose that the cysteine modifications elicit
structural alterations in Keap1 that do not bring about the dis-
sociation of the Keap1–Nrf2 interaction, but brings about protein
structural changes that consequently prevent Nrf2 ubiquitination.
Supporting this proposal, conformational changes in Keap1
caused by Nrf2-activating compounds have been observed using a
hydrophobicity probe49. Alternatively, it may also be possible that
modification of Cys151 in the BTB domain affects the orientation
angle of association between Keap1 and Nrf2, resulting in a
change in the distance from ubiquitin to the target lysine residues
in the Neh2 domain of Nrf2. Further structural analyses are
required for revealing the electrophilic inactivation mechanism
of Keap1.
In conclusion, this study has overcome the difficulties of
simultaneous examination of two-site binding mechanism by use
of titration NMR for competitive inhibition and demonstrates
that the Hinge-Latch mechanism is actively utilized in the Nrf2
activation by the autophagy chaperone p62 and by pharmacolo-
gical Keap1–Nrf2 PPI inhibitors, but not by electrophilic Nrf2
inducers. This study thus demonstrates that Keap1 utilizes mul-
tiple mechanisms for Nrf2 activation in response to a wide range
of environmental stresses.
Methods
Chemical reagents. 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and L-SFN were
purchased from Cayman Chemical and Sigma Aldrich, respectively. 1-[2-cyano-
3,12-dioxooleana-1,9(11)-dien-28-oyl] imidazole (CDDO-Im) was purchased from
Namiki Co. Ltd. PRL295 and NG262 were synthesized in accordance with pre-
viously published protocols34,35. Non-phosphorylated p62-KIR peptide
(KEVDPSTGELQSLQ) and phosphorylated p62-pKIR peptide (KEVDP-pS-
TGELQSLQ) were purchased from Toray Research Center.
Protein expression and purification. Mouse Keap1 cDNA covering full-length
Keap1 protein (Met1-Cys624) was inserted into the pET21a vector (Novagen) and
C-terminally fused with 6×His tag. This protein was co-expressed in Escherichia
coli BL21-Gold (DE3) (Novagen) with pG-Tf2 harboring chaperone genes by
culturing in Terrific Broth medium at 37°C. Recombinant protein expression was
induced by adding isopropyl-β-D-thiogalactopyranoside (IPTG; 0.2 mM). After
overnight incubation at 15°C, the bacteria were harvested and mechanically lysed
by sonication on ice (Branson Sonifier 450). The soluble-protein fraction was
recovered by centrifugation at 10,000 rpm for 20 min at 4°C. After purification by
affinity chromatography using Ni-NTA agarose (QIAGEN), Keap1 protein was
further purified with Enrich Q 5 × 50 column (Bio-Rad) and HiLoad 16/60
Superdex 200 PG (Cytiva).
Fig. 7 The Hinge-Latch model updated. Pharmacological Keap1–Nrf2 PPI
inhibitors disrupt the DLGex–Keap1 interaction preferentially to the
ETGE–Keap1 interaction, conforming the concept of the Hinge-Latch model.
Similarly, p62 accumulation disrupts the DLGex–Keap1 interaction
preferentially and activates Nrf2, conforming to the Hinge-Latch model and
supporting the notion that this mechanism operates in physiological as well
as pathological contexts. In contrast, electrophilic Nrf2-activating
compounds activate Nrf2 without disrupting the Neh2–Keap1 interaction,
implying that these Keap1 thiol-modifying chemicals utilize mechanisms
distinct from the Hinge-Latch mechanism.
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GST-TEV-mouse Nrf2-Neh2 cDNA was inserted into the pET15b vector
(Novagen) and N-terminally fused with 6×His-GST tag. The protein was expressed
in E. coli BL21-star (DE3) (Novagen) and the bacteria were cultured in a modified
minimal M9 medium supplemented with 15N-ammonium chloride and 13C6-D-
glucose at 37°C. Expression of the recombinant protein was induced by adding
IPTG (0.5 mM). After overnight incubation at 27°C, the cells were harvested and
mechanically lysed by sonication on ice. The soluble-protein fraction was recovered
by centrifugation at 10,000 rpm for 20 min at 4°C. After purification by affinity
chromatography with Ni-NTA resin (QIAGEN), Neh2 with N-terminal 6×His-
GST tag was cleaved by TurboTEV Protease (Accelagen) and the tag was removed
by affinity chromatography using Ni-NTA resin. The protein was further purified
with a series of column chromatography utilizing Enrich Q 5 × 50 (Bio-Rad) and
Superdex 75 10/300GL (Cytiva).
NMR data collection. NMR sample of 13C/15N-labeled Neh2 domain was pre-
pared at a final concentration of 0.05 mM in 20 mM Tris-HCl buffer (pH 8.0),
100 mM NaCl, and 4 mM TCEP containing 10% D2O. Two-dimensional TROSY-
HSQC spectra50 were acquired from the 13C/15N-labeled Neh2 domain. All NMR
experiments were performed at 298 K on a Bruker 800-MHz spectrometer
equipped with a CryoProbe. The sequence-specific backbone 1HN, 13Cα, 13C′, and
15N and side-chain 13Cβ resonance assignments of 13C/15N-labeled Neh2 domain
were performed by analyzing six 3D triple-resonance NMR spectra, CBCA(CO)
NH, HNCACB, HNCA, HNCOCA, HNCO, and HN(CA)CO experiments51,52. All
spectra were processed on a Linux PC by using the AZARA 2.7 software package
(W. Boucher, www.bio.cam.ac.uk/azara). Spectra were analyzed on a Linux PC
using CcpNmr Analysis version 2.4.053.
NMR titration experiments. For titration experiments of Keap1, 0.05-, and 0.1-
mM unlabeled-Keap1 were added to the 13C/15N-labeled Neh2 sample. For titra-
tion experiments with p62-KIR peptide, 0.05-mM (final) 13C/15N-labeled Neh2,
and 0.1-mM (final) Keap1 were dissolved in 20-mM Tris-HCl buffer (pH 8.0),
100-mM NaCl, and 4-mM TCEP, and the concentrated p62-KIR peptide was
added to the sample. The final concentration of the peptide was 0.25-, 0.5-, 1.0-,
1.5-, and 5-mM (5-, 10-, 20-, 30-, and 100-fold of Neh2) for phosphorylated
p62-KIR, and 1.0- and 5-mM (20- and 100-fold of Neh2) for non-phosphorylated
p62-KIR. For titration experiments with PRL295, NG262, 15d-PGJ2, CDDO-Im
and SFN, 2D TROSY-HSQC spectra of 13C/15N-labeled Neh2, and 13C/15N-labeled
Neh2–Keap1 complex were recorded in the presence of 5% DMSO-d6. Each
compound was dissolved in DMSO-d6 at concentrated condition and added to the
13C/15N-labeled Neh2–Keap1 complex. The final concentration of the solvent in
the measured sample was 5%. The final concentrations of each compound were as
follows; 0.025-, 0.05-, 0.1-, 0.15-, and 0.25-mM for both PRL295 and NG262, 0.05-,
0.25- and 0.55-mM for 15d-PGJ2, 0.05-, 0.1-, and 0.5-mM for CDDO-Im, and 0.2-
and 0.5-mM for SFN, respectively. For titration experiments with 15d-PGJ2,
CDDO-Im and SFN, 20-mM Tris-HCl (pH 8.0), 100-mM NaCl, and 1-mM
TCEP were used as buffer. The relative intensities of the TROSY-HSQC signals of
13C/15N-labeled Neh2 in the absence or presence of Keap1, p62-KIR peptide, and
chemical compounds were plotted against the number of amino acids of Neh2.
Analyses of the relative intensity changes were performed using CcpNmr Analysis
version 2.4.0.
Statistics and reproducibility. A sufficient number of scans were used for all
NMR experiments to obtain good signal-to-noise. All attempts to replicate the data
were successful.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The source data for the graphs in the figures are available as Supplementary Data 1. All
other data are available from the corresponding authors upon reasonable request.
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